Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Neoplasms 2Neoplasm Metastasis 2Nelson Syndrome 2Multiple Myeloma 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neuroectodermal Tumors, Primitive 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × pasireotide × Clear all
NCT02215070 2021-11-17

Pasireotide in Prevention of GI Toxicity

Duke University

Phase 2 Completed
37 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡